Mo et al. reported that the relative expression level of circulating CCNB2 mRNA in cancer patients (not including ACC) was significantly higher than that in normal controls and a group with benign diseases, and that expression levels of circulating CCNB2 mRNA in cancer patients significantly decreased after treatment [58]. This evidence concerns the gene CCNB2 and adrenal cortex carcinoma.